• Earlier this month, Bausch + Lomb launched its Bi-Blade+ advanced dual-port vitrectomy cutter in Europe on the Stellaris Elite Vision Enhancement System, highlighting technology designed to improve cutting efficiency, fluidics control and intraocular pressure stability in vitreoretinal surgery.
• At the same time, the company’s Vision 27 program and expanding dry eye portfolio, including strong MIEBO prescription growth, have supported a large increase in adjusted EBITDA and leaner operating margins, underscoring how operational execution and innovation are working together across its portfolio.
• We’ll now examine how the European Bi-Blade+ launch, with its higher vitreous flow and reduced cutter vibration, influences Bausch + Lomb’s investment narrative.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Bausch + Lomb Investment Narrative Recap

To own Bausch + Lomb, you need to believe that its broad eye health portfolio and Vision 27 efficiency efforts can turn revenue growth into sustainable profitability, despite current losses. In the near term, the key catalyst is continued execution in higher margin areas like dry eye and premium surgical tools, while the biggest risk is that competitive and pricing pressure blunt this progress. The Bi-Blade+ European launch is positive for the surgical story, but not yet a major short term swing factor.

The Bi-Blade+ launch sits alongside a series of product and clinical updates, but the most relevant recent announcement is Q1 2026 results and raised 2026 revenue guidance to US$5.420–5.520 billion. Together, stronger guidance and ongoing Bi-Blade+ and enVista Envy rollouts frame how innovation in surgical and pharma could support Vision 27’s margin aims, while still leaving execution risk firmly on the table.

Yet even as Bi-Blade+ supports the surgical growth case, investors should be aware that rising competition and pricing pressure across dry eye, lenses and premium IOLs could...

Bausch + Lomb's narrative projects $5.9 billion revenue and $252.2 million earnings by 2028. This requires 5.7% yearly revenue growth and a $557.2 million earnings increase from -$305.0 million today.

Uncover how Bausch + Lomb's forecasts yield a $17.25 fair value, a 7% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue of about US$6.0 billion and US$242.7 million of earnings by 2028, so this Bi-Blade+ launch could either reinforce their higher growth, higher margin view or prompt a rethink, underscoring how your outlook on competition and pricing risk can lead to very different conclusions.

Explore 5 other fair value estimates on Bausch + Lomb - why the stock might be worth over 2x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Bausch + Lomb research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Bausch + Lomb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bausch + Lomb's overall financial health at a glance.

Contemplating Other Strategies?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
• Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.